Priority Date: 11.03.10 (US 20100312895P)

Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers

  • Application ID: EP14196121
  • Status: EXAMINATION IN PROGRESS

Applicant

Technology company logo small
Technology Company

Attorney

no operation time available
1128.02
Headquarter in London and 4 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY) J A Kemp is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 189 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 11.03.2010 - Priority Date (US 20100312895P)
  • 15.04.2015 - Publication A1 (EP2859893)